3M (MMM) Q1 2025 earnings summary

Executive summary

• Q1 2025 adjusted EPS was $1.88, up 10% year-over-year, with organic sales growth of 1.5% and adjusted sales of $5.8B, while GAAP EPS rose 61% to $2.04 and GAAP sales were $6.0B, down 1.0% year-over-year.

• Operating margin improved to 23.5% (adjusted, up 220 bps YoY) and 20.9% (GAAP, up 180 bps YoY), driven by productivity and cost controls.

• Free cash flow reached $0.5B with a 48% conversion rate, and $1.7B was returned to shareholders through dividends and share repurchases.

• 62 new products were launched in Q1, up 60% year-over-year, with improved on-time launch attainment and innovation momentum.

• Completed Solventum (Health Care) spin-off in April 2024, now reported as discontinued operations.

Financial highlights

• Adjusted sales were $5.8B, with organic growth of 1.5% year-over-year; GAAP sales were $6.0B, down 1.0%.

• Adjusted operating margin was 23.5%, up 220 bps year-over-year; GAAP margin was 20.9%, up 180 bps.

• Adjusted EPS was $1.88, up $0.17 or 10% year-over-year; GAAP EPS was $2.04, up 61%.

• Free cash flow was $0.5B, with a 48% conversion rate; $1.7B returned to shareholders, including $1.3B in share repurchases.

• Net income from continuing operations was $1.12B, up from $705M year-over-year.

Outlook and guidance

• 2025 adjusted EPS guidance is $7.60–$7.90, with tariff sensitivity of $(0.20) to $(0.40) per share.

• Organic sales growth is expected at the lower end of the 2%–3% range due to macro softness.

• Operating margins and earnings are expected to be split evenly between the first and second half of the year.

• Continues to expect PFAS manufacturing exit by end of 2025 and ongoing restructuring actions.

• No GAAP EPS guidance provided due to unpredictability of special items.